MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1128/aac.00815-24

Медицинская библиотека · Antimicrobial agents and chemotherapy · 2025

Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.

Lazzaro Alessandro, Recchia Gregorio Egidio, Alessi Federica, Santinelli Letizia, Battistini Luigi, Morcos Julieta, Romano Francesco, Bugani Ginevra, Maddaloni Luca, Caruso Sara, D'Amico Marta, Mezzaroma Ivano, Falciano Mario, Fimiani Caterina, Sfara Germana, Leone Maria Gemma, Turriziani Ombretta, Mastroianni Claudio Maria, d'Ettorre Gabriella

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Doravirine (DOR) is a novel antiretroviral agent with a favorable resistance profile and high tolerability. However, evidence is limited on DOR among elderly people living with HIV (PLWH) and whether it might modulate chronic inflammation. We aimed to investigate the efficacy, safety, and tolerability of DOR as a switching strategy among elderly PLWH and its impact on chronic inflammation in a real-life setting. We recruited a cohort of ART-experienced PLWH undergoing a therapeutic switch to a DOR-based regimen under virologic control (defined as HIV-RNA <200 copies/mL), regardless of the previous ART regimen. The primary objective was the evaluation of the rate of virologic control at 48 weeks post-switch. Secondary objectives included analyzing immune and metabolic outcomes. Plasmatic hs-CRP, IL-6, and D-dimer levels were measured as chronic inflammation markers. Overall, 150 PLWH were screened, and 147 were enrolled into the study. A total of 134 PLWH completed the follow-up. The rate of virological control was 96.1% (122/134; CIs: 91.0%-98.7%) in the per-protocol analysis. After 48 weeks from the switch, we recorded significant reductions in serum fasting glycemia (P 0.019), triglycerides (P 0.024), and total cholesterol/HDL ratio (P 0.017); no clinically significant differences were detected in the body weight and BMI, as long as in immune, hepatic, and renal profiles. A significant reduction in IL-6 (P 0.019) and hs-CRP (P 0.019) was observed. DOR is an effective and safe treatment choice for elderly PLWH. The intriguing modulatory effect of DOR-based regimens on chronic systemic inflammation deserves further investigation.

Для цитирования: Lazzaro Alessandro, Recchia Gregorio Egidio, Alessi Federica, Santinelli Letizia, Battistini Luigi, Morcos Julieta, Romano Francesco, Bugani Ginevra, Maddaloni Luca, Caruso Sara, D'Amico Marta, Mezzaroma Ivano, Falciano Mario, Fimiani Caterina, Sfara Germana, Leone Maria Gemma, Turriziani Ombretta, Mastroianni Claudio Maria, d'Ettorre Gabriella. Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.. Antimicrobial agents and chemotherapy. 2025. DOI: 10.1128/aac.00815-24.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.